BBI Solutions, Cardiff, UK, has launched a line of antibodies for the biomarker galectin-3. The antibodies complement BBI’s galectin-3 antigen, which was launched earlier in 2016. Available to sample, the antibodies are highly sensitive with low cross-reactivity. Galectin-3 has been recognized as a potential biomarker for heart failure, fibrosis, and a variety of cancer types. The antibodies have been tested within sandwich enzyme-linked immunosorbent assays, including in a human serum matrix, and can detect galectin-3 levels as low as 0.025 ng/ml. For more information, visit BBI Solutions.
February 18, 2009
January 20, 2011